Optimal Biomarker Cutoff Identification and Validation

Simon R, Wang S (2006) Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenom J 6(3):166–173

National Research Council (2011) Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. National Academies Press, Washington

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S et al (2016) Pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833

Jiang W, Freidlin B, Simon R (2007) Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 99(13):1036–1043

Liu Y, Tang S-Y, Man M, Li YG, Ruberg SJ, Kaizar E, Hsu JC (2016) Thresholding of a continuous companion diagnostic test confident of efficacy in targeted population. Stat Biopharm Res 8(3):325–333

Freidlin B, Simon R (2005) Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 11(21):7872–7878

von Seggern D (2006) CRC standard curves and surfaces with mathematica, 2nd edn. Taylor & Francis, Abingdon

Shapiro A (2003) Scheffe’s method for constructing simultaneous confidence intervals subject to cone constraints. Stat. Prob. Lett. 64(4):403–406

Genz A, Bretz F (1999) Numerical computation of multivariate t-probabilities with application to power calculation of multiple contrasts. J Stat Comput Simul 63(4):103–117

Lin H-M, Xu H, Ding Y, Hsu JC (2019) Correct and logical inference on efficacy in subgroups and their mixture for binary outcomes. Biometr J 61(1):8–26